wire

# "Science Wire" gibt letzten Meldungen von Forschungsinstitutionen und F&E Unternehmen.
Kategorie


Unternehmen/Institution
ABB | AGROSCOPE | BAFU | CERN | EMPA | EPFL | ETHZ | FHNW | FMI | HSLU | HTWCHUR | NOVARTIS | PSI | ROCHE | SBFI | SNF | UNIBAS | UNIBE | UNIFR | UNIGE | UNIL | UNILI | UNINE | UZH | VOGELWARTE | ZHAW |

Novartis

Betriebswissenschaft/VWL - Medizin/Pharmakologie
08:00
Novartis delivered solid sales and profit growth in the first quarter of 2014
Net sales of USD 14.0 billion up 1% (+3% cc ) with all divisions contributing to growth (cc); core operating leverage (cc) driven by Pharmaceuticals and lower Corporate costs Operating income of
Medizin/Pharmakologie - Biowissenschaften
23.04.2014
New data at AAN to confirm efficacy of Novartis’ Gilenya across four key measures of MS disease activity, including brain volume loss
Gilenya reduced relapse rates, new MRI lesion counts, brain volume loss and disability progression in previously-treated MS patients with high disease activity Data at AAN showed significantly more Gilenya-treated patients (vs.
Medizin/Pharmakologie - Biowissenschaften
23.04.2014
Novartis and Anne Geddes unveil inspirational eBook featuring meningitis survivors in honor of World Meningitis Day
Protecting Our Tomorrows: Portraits of Meningococcal Disease eBook features 15 survivors from around the world; eBook available for free download on iBooks Approximately 500,000 cases of m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
22.04.2014
Novartis announces portfolio transformation
Acquires GSK oncology products, strengthening Novartis' leading Oncology business with novel therapies and becomes GSK's preferred commercialization partner for its oncology pipeline Combines No
Medizin/Pharmakologie - Betriebswissenschaft/VWL
09.04.2014
Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz
Basel, April 9, 2014 - Novartis announced today the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014.
Medizin/Pharmakologie - Biowissenschaften
07.04.2014
Novartis meningitis B vaccine Bexsero receives FDA Breakthrough Therapy designation in the US
The designation highlights the potential of Bexsero to meet the urgent need for a licensed vaccine in the US against unpredictable and devastating meningitis B Bexsero, already approved in Eur
Medizin/Pharmakologie - Betriebswissenschaft/VWL
07.04.2014
Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
One million antimalarial treatments donated by Novartis, matching one million treatments funded through Malaria No More's Power of One campaign Power of One enables the public to fund malari
Medizin/Pharmakologie - Biowissenschaften
03.04.2014
Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways
More than 50 abstracts highlight breadth and depth of Novartis Oncology pipeline and ability to test various combinations early to target multiple pathways Data show activity of investigationa
Medizin/Pharmakologie - Betriebswissenschaft/VWL
31.03.2014
PARADIGM-HF trial of Novartis’ LCZ696 for chronic heart failure closes early based on strength of interim results
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
27.03.2014
Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m&p
Medizin/Pharmakologie - Betriebswissenschaft/VWL
26.03.2014
Study published in NEJM showed LDK378 demonstrated an overall response rate of 58% in patients with ALK+ NSCLC
Novartis study published in NEJM showed LDK378 demonstrated an overall response rate of 58% in patients with ALK+ NSCLC Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months Patients with this type of lung cancer, especially those for whom prior therapies have failed, are in need of new treatment options[1] Data served as the basis for regulatory applic
Medizin/Pharmakologie
22.03.2014
New phase III psoriasis data show rapid, significant skin clearance
New phase III psoriasis data show rapid, significant skin clearance and convenient administration with Novartis' secukinumab (AIN457) Pivotal phase III FEATURE and JUNCTURE studies met primary and pre-specified secondary endpoints, showing high efficacy with convenient pre-filled syringe (PFS) and autoinjector/pen (AI)[1],[2] Patient-reported outcomes from FEATURE and JUNCTURE show high patient satisfaction with secukinumab
Medizin/Pharmakologie - Betriebswissenschaft/VWL
21.03.2014
Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria (CIU)
Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.
Medizin/Pharmakologie - Betriebswissenschaft/VWL
21.03.2014
UK recommends Novartis Bexsero vaccine for inclusion in National Immunisation Programme to help protect against devastating meningitis B
UK recommends Novartis Bexsero vaccine for inclusion in National Immunisation Programme to help protect against devastating meningitis B Following further review of evidence, JCVI recommend
Medizin/Pharmakologie - Betriebswissenschaft/VWL
21.03.2014
Novartis announces start of new secukinumab (AIN457) versus Stelara (ustekinumab) phase IIIb head-to-head psoriasis study at AAD 2014
Novartis announces start of new secukinumab (AIN457) versus Stelara (ustekinumab) phase IIIb head-to-head psoriasis study at AAD 2014 Global phase IIIb head-to-head study of secukinumab versu
Medizin/Pharmakologie - Betriebswissenschaft/VWL
20.03.2014
Novartis introduces Lucentis in state of the art pre-filled syringe
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
19.03.2014
Novartis reports data at EBCC-9 for secondary survival endpoint of Afinitor trial in HR+/HER2- advanced breast cancer
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
13.03.2014
Novartis Bexsero meningitis B vaccine receives clinical recommendation for use in infants and adolescents in Australia
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
07.03.2014
Novartis announces positive Phase III study for Jakavi in patients with rare blood cancer polycythemia vera
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
06.03.2014
Novartis announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria (CSU) patients unresponsive to antihistamines
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Biowissenschaften
28.02.2014
Novartis marks Rare Disease Day with call for more research to understand and find treatments for rare diseases
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a]
Medizin/Pharmakologie - Betriebswissenschaft/VWL
26.02.2014
Novartis extends leadership in clinical trial data transparency, reinforcing its support of clinical research and innovation
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a]
Medizin/Pharmakologie - Betriebswissenschaft/VWL
25.02.2014
Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
21.02.2014
Novartis shows continued commitment in Japan with Lucentis approval in fourth Japanese indication, diabetic macular edema
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a]
Medizin/Pharmakologie - Betriebswissenschaft/VWL
19.02.2014
Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
17.02.2014
Novartis expands cancer immunotherapy research program with acquisition of CoStim
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Betriebswissenschaft/VWL - Medizin/Pharmakologie
29.01.2014
Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
27.01.2014
Novartis recognized among world’s most sustainable companies in Corporate Knights Global 100
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
24.01.2014
Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
24.01.2014
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
12.01.2014
Hervé Hoppenot, President of Novartis Oncology, leaves Novartis to pursue career opportunity outside of organization
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
19.12.2013
Sandoz begins Phase III clinical trial for biosimilar adalimumab
Sandoz advances leading biosimilars pipeline by strengthening Immunology portfolio Global program marks Sandoz' sixth biosimilar molecule to enter Phase III testing Trial will support regis
Medizin/Pharmakologie - Betriebswissenschaft/VWL
18.12.2013
Sandoz receives first approval for AirFluSal Forspiro
Novel inhaler approved for patients with asthma and COPD Approval follows completion of EU decentralized procedure (DCP) AirFluSal Forspiro strengthens Sandoz respiratory port
Medizin/Pharmakologie
09.12.2013
Novartis drug Jakavi improved overall survival of patients with myelofibrosis in four separate analyses of long-term Phase III studies
In two Phase III studies, Jakavi reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with and without high-risk mutations Separate analysis shows Jakavi may increase the probability of 10-year survival of myelofibrosis patients by more than 50% compared to conventional therapy Jakavi is the only JAK inhibitor ap
Medizin/Pharmakologie - Chemie
09.12.2013
New five-year data support superiority of Novartis drug Tasigna over Glivec in newly diagnosed Ph+ CML patients
ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec Data demonstrated higher rates of early and deepe
Medizin/Pharmakologie - Biowissenschaften
07.12.2013
Novartis highlights research on investigational, personalized’T cell therapy CTL019 in patients with forms of acute and chronic leukemia
Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia , , , Presentations include findings that 19 of 22 pediatric patients with acute lymphoblastic leukemia ( ALL) (86%) experienced complete remissions Novartis and Penn exclusive global collaboration to develop chimeric antigen receptor (CAR) technology is moving forward with the goal
Medizin/Pharmakologie
06.12.2013
Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study
Study of LBH589 plus bortezomib and dexamethasone met primary endpoint of extending PFS compared to bortezomib plus dexamethasone and placebo LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma Data will be presented at an upcoming medical congress and discussed with regulatory authorities worldwide Basel, December 6, 2013 - Novartis today announced that
Medizin/Pharmakologie
05.12.2013
Novartis Africa Day highlights company’s efforts to expand access to healthcare
Africa's healthcare challenges are compounded as it begins to face a dual disease burden as non-communicable diseases rise In addition to existing corporate responsibility efforts such as its
Medizin/Pharmakologie - Chemie
04.12.2013
Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS
Multiple studies evaluating deep molecular response with Tasigna versus Glivec in Ph+ CML patients Overall survival data from Jakavi Phase III trials in patients with
Medizin/Pharmakologie
29.11.2013
Novartis Foundation launches new leprosy strategy at symposium on disease elimination
Experts present lessons learned from past control programs and new approaches to eliminating diseases such as leprosy and malaria.
Medizin/Pharmakologie - Betriebswissenschaft/VWL
22.11.2013
Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments
Novartis takes action to strengthen portfolio and capital allocation, starts share buyback Blood transfusion diagnostics unit divested as part of ongoing portfolio management Reiterates opti
Medizin/Pharmakologie
14.11.2013
Novartis announces positive clinical trial results for novel H7N9 vaccine
85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59 adjuvant Vaccine now in large scale
Medizin/Pharmakologie - Betriebswissenschaft/VWL
11.11.2013
Logo Careerjet